Edition:
United States

Virbac SA (VIRB.PA)

VIRB.PA on Paris Stock Exchange

123.00EUR
16 Feb 2018
Change (% chg)

€2.20 (+1.82%)
Prev Close
€120.80
Open
€120.80
Day's High
€123.60
Day's Low
€120.80
Volume
5,940
Avg. Vol
13,386
52-wk High
€173.35
52-wk Low
€102.10

Chart for

About

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus... (more)

Overall

Beta: 0.88
Market Cap(Mil.): €1,040.33
Shares Outstanding(Mil.): 8.46
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Virbac Q4 Sales Up At 231.5 Million Euros

* ANNUAL SALES COMPARABLE TO 2016 AT CONSTANT EXCHANGE RATES AFTER STRONG FOURTH-QUARTER GROWTH

Jan 16 2018

BRIEF-Virbac postpones its option to buy Centrovet for three years

* REG-VIRBAC : AQUACULTURE: VIRBAC POSTPONES ITS OPTION TO BUY CENTROVET FOR THREE YEARS

Nov 22 2017

BRIEF-Virbac Q3 sales fall to 192.7 million euros

* REG-VIRBAC: QUARTERLY SALES AFFECTED BY DISTRIBUTOR DESTOCKING IN THE UNITED STATES

Oct 12 2017

Virbac cuts full-year revenue forecast amid still weak US sales

Sept 11 French veterinary pharmaceutical firm Virbac cut its full-year outlook on Monday, saying it now expected revenue to be little changed from last year after a fall in U.S. sales affected its first-half earnings.

Sep 11 2017

BRIEF-Virbac H1 net profit group share rises to 13.9 ‍million euros

* H1 NET PROFIT GROUP SHARE EUR 13.9 ‍​MILLION VERSUS EUR 13.1 MILLION YEAR AGO

Sep 11 2017

Earnings vs. Estimates